9 April 2026 in Pharmacia
Background : Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease progression and increased cardiovascular risk in patients with type 2 diabetes mellitus (T2DM). Despite optimized standard therapy, substantial residual renal risk persists. Finerenone, a selective non-steroidal mineralocorticoid receptor antagonist, has demonstrated cardiorenal benefits in large randomized clinical trials. Materials and methods : This single-center retrospective observational study included 82 adult patients with T2DM and DKD treated with finerenone as add-on therapy to standard care. Renal parameters—including serum creatinine, estimated glomerular filtration rate (eGFR), microalbuminuria, urine albumin-to-creatinine ratio (UACR), and serum potassium—were evaluated at baseline and after 6–12 months of therapy. Data are presented as mean ± SD. A paired student’s t-test or Wilcoxon test was used as appropriate, with p < 0.05 considered statistically significant. Results : Mean age was 68.1 ± 10.2 years, and 54.9% of patients were women. After therapy, serum creatinine increased modestly (Δ +2.9%, p < 0.001), while eGFR declined slightly (Δ −4.4%, p < 0.001). Significant reductions were observed in microalbuminuria (Δ −16.6%, p < 0.001) and UACR (Δ −21.0%, p < 0.001). Serum potassium increased (Δ +9.5%, p < 0.001), remaining within clinically acceptable limits. Subgroup analysis demonstrated significant UACR reduction across different albuminuria categories. Conclusion : In patients with T2DM and DKD, finerenone therapy was associated with significant reductions in albuminuria and modest changes in renal function parameters during routine follow-up. These findings are consistent with data from randomized clinical trials and support the role of finerenone as part of a comprehensive therapeutic approach in albuminuric DKD.
16 September 2026 in Pharmacia
Background : Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare systemic autoimmune disease characterized by necrotizing inflammation of small blood vessels. Pulmonary–renal syndrome represents one of the most severe clinical manifestations and is associated with high morbidity, rapid progression of renal failure, and increased mortality. Management requires individualized immunosuppressive therapy, careful pharmacological monitoring, and multidisciplinary care. Case presentation : The case of a 54-year-old male with proteinase 3 (PR3)-ANCA-positive vasculitis complicated by rapidly progressive glomerulonephritis, pulmonary infiltrates, and dialysis-dependent acute kidney injury is presented. The initial presentation mimicked severe infection and possible malignancy, which complicated the diagnostic process. Despite induction therapy with corticosteroids and cyclophosphamide, renal recovery was not achieved. Due to refractory disease activity and concerns regarding cumulative cyclophosphamide toxicity, rituximab therapy was initiated. Stabilization of systemic inflammatory activity and regression of pulmonary involvement were subsequently observed, although renal replacement therapy remained necessary. Conclusion : This case highlights the complexity of therapeutic decision-making in severe ANCA-associated pulmonary–renal syndrome. Rituximab represented an effective individualized therapeutic option in a dialysis-dependent patient with refractory disease. Careful pharmaceutical management, infection surveillance, and multidisciplinary monitoring remain essential during biologic immunosuppressive therapy.